BeiGene to build new manufacturing and R&D center in the Garden State


Among focal points, New Jersey location will support clinical research, pharmacovigilance

BeiGene, Ltd., a global biotech company that develops and commercializes cancer medicines, plans to build a new campus for R&D and manufacturing at the Princeton West Innovation Campus in Hopewell, NJ. The company has entered into a purchase agreement to acquire an approximately 42-acre site with over one million square feet of developable real estate, to construct a state-of-the-art facility that is expected to include commercial-stage biologic pharma manufacturing, clinical R&D and the BeiGene Center for Pharmacovigilance Innovation.

Construction is anticipated to be completed by mid-2023, but in the meantime, BeiGene plans to rent space nearby and begin hiring as soon as possible.

The biotech company chose to build its new manufacturing and clinical R&D center in Hopewell, given its central location and proximity to pharmaceutical research, development and manufacturing talent, along with the possibility of expanding the aforementioned 42-acre parcel that is planned to support the company’s growth strategy.

“BeiGene continues to grow, and as a key part of that growth, we are making a significant investment in the United States that will expand our current capabilities,” notes Michael Garvey, the company’s global head of technical operations. “This endeavor, once complete, will further expand and diversify our global supply chain and build new manufacturing capabilities for our world-class pipeline.”

Related Videos
© 2024 MJH Life Sciences

All rights reserved.